好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence and Associations of Peripheral Neuropathy at Disease Onset in ANCA-Associated Vasculitides: Insights from the DCVAS Study
Neuromuscular and Clinical Neurophysiology (EMG)
S58 - Therapeutics in Neuromuscular Disorders (1:11 PM-1:22 PM)
002
Reported prevalence and associations of vasculitic neuropathy (VN) with other organ manifestations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are highly variable given the lack of diagnostic certainty for peripheral nerve involvement in the setting of systemic vasculitis.

To describe the prevalence, characteristics, and associations of VN with other disease manifestations in new-onset AAV in the DCVAS (diagnosis and classification of vasculitis) study and stratify for diagnostic certainty of VN.

From a prospective cross-sectional observational study (DCVAS) conducted at 135 centers worldwide, 1268 patients had an investigator-assigned diagnosis of AAV. 955 patients (mean age 57, range 18-91 years, 51% female), in whom the diagnosis was confirmed by an expert panel, were included in the final analysis. 572 had granulomatosis with polyangiitis (GPA), 218 microscopic polyangiitis (MPA)and 165 eosinophilic granulomatosis with polyangiitis (EGPA).

Presence of VN was categorized as definite (histology proven), probable (multiple mononeuropathy or nerve biopsy consistent with vasculitis) or possible (all others). Patients with possible VN and positive other-organ biopsy were sub-categorized as “possible+”. Associations with laboratory findings and other organ manifestations were compared in patients with and without VN.

269/955 (28%) AAV patients had VN. Prevalence was 65% EGPA, 23% MPA, and 19% GPA. Nerve biopsy was performed in 32/269 (12%) patients. Diagnostic certainty for VN was definite 6%, probable 38%, and possible 56%. 46% of possible cases were categorized possible+. VN was associated with skin (p<0.001), musculoskeletal (p<0.001) and cardiovascular (p=0.005) involvement. VN patients were less likely to have renal (p<0.001), eye (p<0.001) and gastrointestinal (p=0.023) involvement. VN was associated withMPO-ANCA-positivity (p=0.004).

 

Our study gives a comprehensive insight into prevalence and organ associations of VN in a large, systematically collected AAV cohort. VN is most commonly associated with skin and musculoskeletal manifestations. In routine clinical practice diagnosis of VN is rarely confirmed by nerve biopsy.
Authors/Disclosures
Antje Bischof, MD
PRESENTER
Dr. Bischof has nothing to disclose.
No disclosure on file
Robert D. Hadden, MBBS, PhD Dr. Hadden has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Hadden has received personal compensation in the range of $0-$499 for serving as a Consultant for Dianthus Therapeutics. Dr. Hadden has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Hadden has received personal compensation in the range of $5,000-$9,999 for serving as a travel expenses to attend conference with CSL Behring.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Michael P. Collins, MD (Medical College of WI-Dept. of Neurology) No disclosure on file
No disclosure on file